# Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC

> **NCT06100497** · PHASE2 · RECRUITING · sponsor: **Beijing Tongren Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Cisplatin
- **DRUG:** Paclitaxel-albumin

## Key facts

- **NCT ID:** NCT06100497
- **Lead sponsor:** Beijing Tongren Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-01
- **Primary completion:** 2025-10-31
- **Final completion:** 2028-10-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06100497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06100497, "Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06100497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*